RSS   Newsletter   Contact   Advertise with us
Post Online Media
Post Online Media Magazine

Lilly to buy cancer drug developer AurKa Pharma for up to $575 million

Share on Twitter Share on LinkedIn
Staff Writer |
Eli Lilly and Company
Acquisition   AurKa Pharma will receive $110 million upfront

Eli Lilly and Company will buy AurKa Pharma in a deal potentially worth up to $575 million.

AurKa Pharma will receive $110 million upfront and is eligible to earn up to $465 million more if it achieves regulatory and sales milestones.

AurKa’s chief drug under development was discovered by Lilly, but the drugmaker sold the compound in 2016 to TVM Capital Life Science, which established AurKa.

The drug, AK-01, is being studied in early-stage trials to treat multiple types of solid tumors.

What to read next
POST Online Media Contact